Literature DB >> 7545344

Potentiality of gelatin microsphere as immunological adjuvant.

R Nakaoka1, Y Tabata, Y Ikada.   

Abstract

This paper describes a new attempt to enhance the production of antibody by delivery of an antigen to phagocytic antigen-presenting cells (e.g. macrophages) using gelatin microspheres. A model protein antigen, human gamma globulin (HGG), was incorporated into microspheres composed of gelatin which have an opsonic ability for macrophage phagocytosis. Subcutaneous injection of the microspheres induced the production of HGG-specific IgG antibody in the mouse serum to a great extent compared with that of HGG in soluble form or in Freund's incomplete adjuvant (FIA) form. There was an optimal concentration of cross-linking agent (glutaraldehyde) for the highest production of antibody. When gelatin microspheres were cross-linked at lower concentrations of glutaraldehyde, they were more extensively swollen in an aqueous solution, leading to an increase in the size of hydrated microspheres because of their lower cross-linking densities. The increased size of microspheres caused a decrease in their macrophage phagocytosis, whereas the release rate of HGG from the microspheres increased as the concentration of cross-linking agent became low. The balance of the two factors, the microsphere susceptibility to macrophage phagocytosis and the rate of HGG release, seemed to affect the efficacy of gelatin microspheres to enhance the antibody production. In addition, incorporation of HGG into gelatin microspheres enhanced the delayed-type hypersensitivity reaction. Moreover, the microspheres developed a strong secondary response in comparison with FIA. The gelatin microspheres induced a minimal inflammatory response around the injection site in contrast to FIA. These findings demonstrate that the gelatin microsphere is promising as an adjuvant to enhance both humoral and cellular immune responses to antigen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545344     DOI: 10.1016/0264-410x(94)00024-h

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Direct in vivo injection of 131I-GMS and its distribution and excretion in rabbit.

Authors:  Yu Ma; Yi Wan; Dong-Hui Luo; Li-Geng Duan; Lin Li; Chuan-Qin Xia; Xiao-Li Chen
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

2.  A Perspective on Imiquimod Microneedles for Treating Warts.

Authors:  Tsu-Man Chiu; Ping-Chun Hsu; Mohd Yaqub Khan; Cheng-An J Lin; Chun-Hung Lee; Tsai-Ching Hsu; Min-Hua Chen; Nobutaka Hanagata
Journal:  Pharmaceutics       Date:  2021-04-22       Impact factor: 6.321

3.  Exploring geometric properties of gold nanoparticles using TEM images to explain their chaperone like activity for citrate synthase.

Authors:  Vikas Kaushik; Tapobrata Lahiri; Shantiswaroop Singha; Anjan Kumar Dasgupta; Hrishikesh Mishra; Upendra Kumar; Rajeev Kumar
Journal:  Bioinformation       Date:  2011-12-10

4.  Optimization of the spherical integrity for sustained-release alginate microcarriers-encapsulated doxorubicin by the Taguchi method.

Authors:  C T Pan; S T Chien; T C Chiang; C K Yen; S Y Wang; Z H Wen; C Y Yu; Y L Shiue
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.